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ReseaFludarabine-Based Conditioning for Marrow
Transplantation from Unrelated Donors in Severe
Aplastic Anemia: Early Results of a Cyclophosphamide
Dose Deescalation Study ShowLife-Threatening Adverse
Events at Predefined Cyclophosphamide Dose Levels
Jakub Tolar,1 H. Joachim Deeg,2 Sally Arai,3 Mitchell Horwitz,4 Joseph H. Antin,5
John M. McCarty,6 Roberta H. Adams,7 Marian Ewell,8 Eric S. Leifer,9 Iris D. Gersten,8
Shelly L. Carter,8 Mary M. Horowitz,10 Ryotaro Nakamura,11 Michael A. Pulsipher,12
Nancy L. DiFronzo,13 Dennis L. Confer,14 Mary Eapen,10 Paolo Anderlini15Excessive adverse events were encountered in a Phase I/II study of cyclophosphamide (CY) dose deescalation
in a fludarabine-based conditioning regimen for bone marrow transplantation from unrelated donors in pa-
tients with severe aplastic anemia. All patients received fixed doses of antithymocyte globulin, fludarabine,
and low-dose total body irradiation. The starting CY dose was 150 mg/kg, with deescalation to 100 mg/
kg, 50 mg/kg, or 0 mg/kg. CY dose level 0 mg/kg was closed due to graft failure in 3 of 3 patients. CY
dose level 150 mg/kg was closed due to excessive organ toxicity (n5 6) or viral pneumonia (n5 1), resulting
in the death of 7 of 14 patients. CY dose levels 50 and 100mg/kg remain open. Thus, CYat doses of 150mg/kg
in combination with total body irradiation (2 Gy), fludarabine (120 mg/m2), and antithymocyte globulin was
associated with excessive organ toxicity.
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Unrelated donor bone marrow transplantation
(BMT) is an important therapy for patients with severe
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BMT CTN 0301 TREATMENT SCHEMA 
N = 6 total dose CY 150 mg/kg (50 mg/kg Day –4 to –2) 
De-escalation/Escalation
Maximum N = 24-27 (Phase I) 
2-Year Follow-up for Survival 
Comparison to 
External Control 
Deeg et al. regimen6
ATG Day –4 to –2 
Fludarabine Day –5 to –2 
TBI Day –1 
N = 6 total dose CY 100 mg/kg (50 mg/kg Day –3 to –2) 
N = 6 total dose CY 50 mg/kg (50 mg/kg Day –2) 
 N = 6 total dose CY 0 mg/kg  
Phase II
Refine Dose Selection  
and  
Allocate Patients to Optimal Dose  
Phase I 
Test Each Dose for Safety  
and  
Adequate Graft Retention  
De-escalation 
Total accrual = up to 78-81 patients 
 (including Phase I) 
Legend: BMT CTN: Blood and Marrow Transplant Clinical Trials Network; CY: Cyclophosphamide; 
ATG: antithymocyte globulin; TBI: total body irradiation. 
Figure 1. Study design.
1008 Biol Blood Marrow Transplant 18:1007-1011, 2012J. Tolar et al.Kojima et al. [4] reported on 154 patients who un-
derwentBMTafter conditioningwith various regimens.
Five-year overall survival was 56%, and 11% of the pa-
tients experienced graft failure. The conditioning regi-
mens included total body irradiation (TBI; 200-1000
Gy or limited field irradiation), cyclophosphamide
(CY; 120-200 mg/kg), and antithymocyte globulin
(ATG). Deeg and coworkers [5,6] evaluated a TBI
dose deescalation regimen in 87 patients and found
that the optimum TBI dose was 200 cGy given along
with CY (200 mg/kg) and horse ATG (ATGAM 90
mg/kg) [5,6]. Graft failure occurred in 5% of patients.
Overall, 55% of patients were alive; the dose-limiting
toxicity was diffuse pulmonary injury. Recently, the
need for TBI has been called into question, and fludar-
abine (FLU) has been incorporated in some condition-
ing regimens as a possible alternative to low-dose TBI
[7-11]. Although most regimens still use CY, the
drug’s role and dose in combination regimens have not
been well established [1].
The Blood andMarrow Transplant Clinical Trials
Network (BMTCTN) designed amulticenter Phase I/
II study to identify the optimal dose of CY in a BMT
preparative regimen that also incorporates FLU,
ATG, and low-dose TBI [12]. To notify the transplan-
tation community of these critical interim results, we
now report serious adverse events in the 2 of 4 study co-horts with the highest (150 mg/kg) and the lowest
(0 mg/kg) CY dose levels. The trial continues to accrue
patients to the 50 mg/kg and 100 mg/kg dose levels.PATIENTS AND METHODS
BMT CTN 0301 is a Phase I/II study evaluating
the optimal dose of CY within a preparative regimen
of FLU, ATG, and TBI before unrelated BMT for
SAA. The trial is registered at www.clinicaltrials.gov
(NCT00326417). The study protocol has been ap-
proved by the Institutional Review Board at each par-
ticipating center. Written informed consent is
obtained in accordance with the Declaration of Hel-
sinki before the initiation of conditioning therapy. El-
igibility criteria are SAA, age up to 65 years, adequate
organ function, and an available unrelated adult mar-
row donor matched for HLA-A, -B, -C, and -DRB1
ormismatched at a single locus. Transplantation of pe-
ripheral blood progenitor cells is prohibited, in view of
the inferior patient outcome with this stem cell prod-
uct in related donor transplantation [13], as was re-
cently confirmed in a study of unrelated donor
transplantation [14]. Patients with Fanconi anemia or
other marrow failure syndromes are excluded.
All patients receive a fixed dose of ATG (either thy-
moglobulin 3mg/kg i.v. or ATGAM30mg/kg i.v. daily
Table 1. Patient Characteristics and Outcomes
Patient
CY Dose,
mg/kg
Time from
Diagnosis to
BMT, Months
Age,
Years
HLA
Match
Previous
Immunosuppressive
Treatment
TNC Dose
Infused,  107/kg
Recipient–Donor
Sex Match
Recipient–Donor
CMV Match Engraftment/Graft Failure Survival Status Cause of Death
1 0 17 22 7/8 ATG, S 23.5 M/M P/N Engrafted at day 22; secondary
graft failure at day 29
Died, day 114 ARDS (diffuse alveolar
damage at postmortem)
2 0 62 17 8/8 ATG, S, CSA 10.8 F/M P/P Engrafted at day 23; secondary
graft failure at day 84
Alive, day 732 —
3 0 7 61 8/8 ATG, CSA 0.29 F/F P/P Engrafted at day 24; secondary
graft failure at day 52
Died, day 200 CMV pneumonia
4 150 5 16 8/8 ATG, S, CSA 36.0 M/M P/P Engrafted, day 21 Alive, day 838 —
5 150 7 5 8/8 No treatment 30.0 F/M P/N Engrafted, day 20 Alive, day 742 —
6 150 7 8 8/8 ATG, S, CSA 55.4 F/F N/N Engrafted, day 26 Alive, day 704 —
7 150 19 18 8/8 ATG, S, CSA 44.5 F/F P/N Engrafted, day 22 Alive, day 763 —
8 150 21 18 8/8 ATG, CSA, MMF 19.8 F/F P/N Engrafted, day 26 Alive, day 703 —
9 150 12 15 8/8 ATG, S, CSA 38.8 F/F N/P Engrafted, day 31 Died, day 135 Pulmonary failure
10 150 44 17 7/8 Androgens, ATG, S,
CSA, sirolimus
32.1 F/F P/U Engrafted, day 22 Died, day 92 ARDS
11 150 77 20 7/8 Unknown 12.1 M/F N/N Engrafted, day 20 Died, day 82 Multiorgan failure
12 150 15 61 8/8 ATG, CSA, 20.0 M/M P/N Primary graft failure by day 42 Died, day 62 Cardiac failure
13 150 15 23 8/8 ATG, CSA,
alemtuzumab
19.7 M/F N/N Engrafted, day 23 Alive, day 817 —
14 150 7 44 8/8 ATG, S, CSA 21.9 F/F P/P Engrafted, day 26 Died, day 148 Parainfluenza virus type 3
pneumonia
15 150 12 52 8/8 ATG, CSA 23.1 F/M P/N NA Died, day 1 ARDS (diffuse acute lung
injury postmortem)
16 150 20 9 7/8 ATG, S, CSA NA M/F P/P NA Died 1 day before
planned BMT
Pulmonary failure
17 150 8 15 7/8 ATG, S, CSA 0.07 F/M N/N Engrafted, day 22 Alive, day 897 —
CSA indicates cyclosporine; S, corticosteroids; ATG, antithymocyte globulin; MMF, mycophenolate mofetil; SAA, severe aplastic anemia; CMV, cytomegalovirus; P, positive; N, negative; U, unknown; ARDS, adult
respiratory distress syndrome; IP, interstitial pneumonia; BMT, bone marrow transplantation; CY, cyclophosphamide; TNC, total nucleated cells; NA, not applicable.
The transplantation in patient 1 was mismatched at the HLA-DRB1 locus. Engraftment was defined as the achievement of an absolute neutrophil count (ANC) $0.5  109/L for 3 consecutive measurements on
different days. Primary graft failure was defined by a lack of neutrophil engraftment, that is, ANC < 0.5  109/L on 3 consecutive measurements on different days by 100 days after transplantation. See the text
for the definition of secondary graft failure.
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1010 Biol Blood Marrow Transplant 18:1007-1011, 2012J. Tolar et al.ondays24 to22), FLU (30mg/m2 i.v. daily on days25
to 22), and low-dose TBI (200 cGy on day 21)
(Figure 1). Graft-versus-host disease prophylaxis is pro-
vided by a calcineurin inhibitor (cyclosporine or tacroli-
mus) and methotrexate. Day 0 is the day of marrow
infusion.
ThePhase I component of the trial tested 4CYdose
levels—150 mg/kg (50 mg/kg/day on days 24 to 22),
100 mg/kg (on days 23 to 22), 50 mg/kg (on
day 22), and 0 mg/kg—to establish the optimal CY
dose. The intention was to test each dose level in 6 pa-
tients, unless graft failure or toxicity boundaries were
crossed, and then enroll additional patients to the opti-
mal dose level in the Phase II portion of the trial, using
adaptive Bayesian criteria to rank the desirability of the
CY doses (Figure 1). Patients were evaluated for graft
failure and early mortality at days 42 and 100. The aim
of the safety monitoring was to minimize the number
of patients treated at a dose level atwhich the probability
of engraftment is too low or the probability of severe
toxicity (including death) is too high, and to maximize
the number of patients treated at the ‘‘optimal’’ dose.
Stopping guidelines were devised incorporating both
endpoints.ThePhase II portionof the trialwas designed
to refine the dose selection and to provide amore precise
estimate of efficacy at the optimal dose.RESULTS AND DISCUSSION
The study opened for accrual in January 2006. As of
June 26, 2011, a total of 61 patients had been enrolled.
Characteristics of patients enrolled at the 0 mg/kg and
150 mg/kg CY dose levels are summarized in Table 1.
The Phase I portion was completed (21 patients
treated) in August 2007. CY dose level 0 mg/kg was
closed in August 2007 during Phase I, because of an ex-
cessive number of graft failures. All 3 enrolled patients
(all treated with thymoglobulin) developed secondary
graft failure (at days 129, 152, and 184), defined as
initial neutrophil engraftment followed by a decline
in the neutrophil count to\0.5  109/L for 3 consec-
utive measurements on different days, unresponsive to
growth factor therapy. All 3 patients received a second
allograft. One patient is alive at 23 months after BMT,
and 2 patients died, one due to interstitial pneumonia
on day1114 and the other from adult respiratory dis-
tress syndrome on day 1200 (Table 1).
At the completion of Phase I, CYdose level 150mg/
kg was chosen as the likely optimal dose, and 8 addi-
tional patients were accrued at this level (total n 5 14).
This dose level was closed inMarch 2008 because of ex-
cessive organ toxicity. Seven of the 14 patients died (in-
cluding 7 of the last 8 enrolled). Four died from organ
failure, 2 from acute respiratory distress syndrome,
and 1 from pneumonia due to parainfluenza virus type
3 infection (Table 1). Accrual continues at CY 100
mg/kg (currently 35 patients). Enrollment is also al-lowed at the CY 50 mg/kg dose level (currently 13 pa-
tients), whereas CY 100 mg/kg has been paused to
allow follow-up of the enrolled patients through the
predefined 42- and 100-day monitoring points. To en-
sure that the CY 50 mg/kg dose level undergoes ade-
quate testing and to achieve a more balanced accrual
in the 2 remaining groups, we have proposed a revised
patient allocation plan that favors the latter dose level
to the study Data Safety Monitoring Board.
The excessive graft failures occurred when CY was
omitted from the regimen. One of the 3 transplants
was mismatched at the HLA-DRB1 locus, and the
other 2 patients received relatively low graft cell doses.
Graft rejection is a recognized complication in these
settings [1]. The lethal organ toxicities (primarily pul-
monary) seen in the CY 150 mg/kg cohort were unex-
pected, given that the safe use of similar (and even
higher) doses of CY has been reported in other trans-
plantation regimens and settings [1,4]. Thus, this
toxicity might have been related to the other agents
in the conditioning regimen. Of note, pulmonary
toxicity is the main adverse effect of even low-dose
TBI [5,6]. Furthermore, the administration of FLU
with high-dose CY may lead to interactions that mag-
nify the known effects of low-dose TBI.
In conclusion, our early analysis of this trial has re-
vealed 2 important findings regarding the regimen
tested in this study. First, the omission of CY was asso-
ciated with a higher-than-expected secondary graft
failure rate, although 2 of 3 patients in this group re-
ceived lower-than-recommended cell doses. Second,
a CY dose of 150 mg/kg was associated with higher-
than-expected transplantation-related mortality. The
current data suggest caution in combining 150 mg/
kg CY, ATG, FLU, and TBI (or in omitting the CY
entirely) in transplantation regimens targeting SAA,
and highlight the need for well-controlled and care-
fully monitored multicenter studies of new dosing reg-
imens before widespread implementation.ACKNOWLEDGMENTS
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